Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in active proliferative lupus nephritis
NCT02547922Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2015
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of anifrolumab in lupus nephritis (LN) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in 24-hour Urine Protein to Creatinine Ratio at 52 weeks. Started Nov 2015; status: completed.
02
Drugs
anifrolumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT02547922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547922.